Buprenorphine is a short-term pain relief medication that's commonly combined with other medications to manage mild to moderate pain in cats. It is usually given subcutaneously (under the skin) or ...
Business Wire: Elanco’s ZORBIUM™ (Buprenorphine Transdermal Solution) – the First Long-Acting Transdermal Buprenorphine for Cats - Gains U.S. Approval
Elanco’s ZORBIUM™ (Buprenorphine Transdermal Solution) – the First Long-Acting Transdermal Buprenorphine for Cats - Gains U.S. Approval
Medication use for opioid use disorder has increased but remains low, and methadone and buprenorphine are linked to reduced risk for opioid overdose, a new study shows.
Higher daily buprenorphine doses may help patients better manage opioid use disorder (OUD), data from a National Institutes of Health (NIH) study suggested.
The new buprenorphine formulation is used as a substitution treatment in adults and adolescents 15 years or older who agree to be treated for addiction.
A randomized trial finds weekly extended-release buprenorphine yields neonatal outcomes comparable to sublingual treatment.
An expert shares his approach to transitioning from opioids to buprenorphine, and starting buprenorphine in opioid-naive patients with chronic pain.
DEA and HHS have delayed implementation of two rules for telehealth prescribing of buprenorphine until the end of the year to review whether the rules are lawful.
The FDA urges manufacturers to revise labeling of transmucosal buprenorphine products to ease access to higher doses because of the rise of high-potency opioids like fentanyl.
Buprenorphine combined with naloxone appeared to be a safer choice for pregnant women with opioid use disorder than buprenorphine alone.
Extended-release buprenorphine ends use of nonprescribed opioids and is safe for mother and baby.